With so many blue chip ASX shares to choose from, it can be hard to decide which ones to buy over others.
To help narrow things down, I have picked out two top blue chip ASX shares that experts rate as buys right now. They are as follows:
CSL Limited (ASX: CSL)
The first blue chip ASX share to consider is CSL. It is one of the world's leading biotechnology companies, comprising the CSL Behring business and the Seqirus business.
The CSL Behring business is the global leader in a plasma therapies industry worth a massive ~US$30 billion per year. Whereas Seqirus is the number two player in the ~US$6 billion global influenza vaccines industry.
While COVID-related plasma collection headwinds have been weighing on CSL's performance, this headwind is now easing. In fact, industry data appears to show that collections are back to pre-COVID levels at long last. This should be supportive of its margins in the coming years, especially as the company rolls out its new collection technology which is expected to collect plasma more efficiently.
In light of this, investors may want to focus more on the long term, which remains very positive for CSL thanks to strong demand for its portfolio of life-saving therapies and vaccines, its lucrative research and development pipeline, and the impending acquisition of Vifor Pharma.
Citi is positive on CSL and currently has a buy rating and $330.00 price target on its shares.
Goodman Group (ASX: GMG)
Another blue chip ASX share to look at is Goodman Group. It is a leading integrated commercial and industrial property company.
Management has expertly developed its portfolio to give it exposure to key growth markets such as ecommerce and logistics. This has been a huge success and been a key driver of Goodman's stellar growth in recent years and again in FY 2022.
For example, in FY 2022, strong demand has led to the company upgrading its earnings guidance numerous times. So much so, it now expects earnings per share growth of 20%+ this year.
The team at Citi is also positive on Goodman. Its analysts continue to believe that Goodman's guidance is conservative and that the company will outperform it. The broker is also forecasting earnings per share growth of almost 20% in FY 2023.
In light of this, it will come as no surprise to learn that Citi has a buy rating and $22.00 price target on Goodman's shares.
